Zoetis Inc. (0M3Q.L) LSE

Currency In USD

AD

Zoetis Inc.

Address

10 Sylvan Way

Parsippany, NJ 07054

United States of America (the)

Phone

973 822 7000

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

13800

First IPO Date

January 29, 2018

Key Executives

NameTitlePayYear Born
Kristin C. PeckChief Executive Officer & Director5.42M1971
Roxanne LaganoExecutive Vice President, General Counsel & Corporate Secretary1.44M1965
Robert J. PolzerScientific Advisor1.45M1969
Jamie BrannanExecutive Vice President & Chief Commercial Officer1.74M1973
Wetteny N. JosephExecutive Vice President & Chief Financial Officer1.8M1972
Abhay U. NayakExecutive VP & President of U.S. Commercial Operations01988
Julie A. FullerExecutive Vice President, Chief Human Resources Officer & Global Operations01973
Keith SarbaughExecutive Vice President & Chief Digital and Technology Officer01979
Steven FrankVice President of Investor Relations0N/A
Jeannette Ferran AstorgaExecutive Vice President of Corporate Affairs & Chief Sustainability Officer01976
Rimma DriscollEVP of Global Strategy, Portfolio Mktg. & Business Dev and Global BioDevices & Platinum Performance01973
Nick AshtonExecutive Vice President and President of Global Manufacturing & Supply01974
Jared ShriverPresident of U.S. Operations0N/A
AD

Description

Zoetis Inc. operates as a prominent global animal health enterprise, dedicated to the research, development, production, and marketing of advanced pharmaceuticals, biologicals, and diagnostic solutions. Its extensive product portfolio targets a broad spectrum of animals, encompassing livestock like cattle, pigs, poultry, fish, and sheep, as well as companion animals such as dogs, cats, and horses, serving both the United States and international markets. The company's offerings include a diverse range of vaccines, designed as biological preparations to prevent afflictions of the respiratory, gastrointestinal, and reproductive systems, or to stimulate a targeted immune response. It also provides anti-infectives that combat or inhibit the proliferation of bacteria, fungi, and protozoa, alongside parasiticides crucial for eradicating or preventing internal and external parasites, such as fleas, ticks, and various worms. Additionally, its pharmaceutical pipeline features products for pain and sedation, antiemetic solutions, reproductive health, and oncology. Zoetis also develops dermatology treatments for allergic skin conditions and atopic dermatitis, alongside medicated feed additives for livestock. Beyond therapeutics, Zoetis is a provider of comprehensive diagnostic tools. These include portable blood and urine analysis systems, point-of-care diagnostics, specialized instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitoring devices. Complementing these are other non-pharmaceutical solutions such as nutritional supplements, agribusiness services, biodevices, genetic testing, and advanced precision animal health technologies. The company distributes its extensive portfolio to a diverse client base, including veterinarians, livestock producers, and retail channels, often working with third-party veterinary distributors. This outreach is supported by its dedicated sales representatives and a team of technical and veterinary operations specialists. Established in 1952, Zoetis maintains its headquarters in Parsippany, New Jersey.

AD